Investigational drug · Phase 3
SPH4336
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced or Metastatic Breast Cancer, Breast Cancer Brain Metastases, Advanced Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
6
Any phase or sponsor naming "SPH4336"
First trial start
2023
Apr 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPH4336", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Breast Cancer
- Breast Cancer Brain Metastases
- Advanced Solid Tumors
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SPH4336" as an intervention, largest first.
- Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast CancerPivotal-lookingRecruiting
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05744687 · 374 participants (planned) · Start Apr 24, 2023 · Primary completion May 31, 2026
Drug: SPH4336 Tablets 400mg; SPH4336 Tablets Placebo · For: Locally Advanced or Metastatic Breast Cancer
Sites: Fuzhou, China; Guangzhou, China; Guiyang, China · 9 sites in all
- Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerPivotal-lookingRecruiting
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05860465 · 254 participants (planned) · Start Sep 8, 2023 · Primary completion Dec 1, 2026
Drug: SPH4336 Tablets; SPH4336 Tablets Placebo · For: Locally Advanced or Metastatic Breast Cancer
Sites: Guangzhou, China; Liuzhou, China; Anyang, China · 22 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05944224 · 63 participants (planned) · Start Oct 17, 2023 · Primary completion Dec 31, 2026
Drug: SPH4336; Cadonilimab · For: Advanced Solid Tumors
Sites: Fuzhou, China; Guangzhou, China; Zhengzhou, China · 16 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05872347 · 52 participants (planned) · Start Sep 19, 2023 · Primary completion Dec 31, 2026
Drug: SPH4336 Tablets · For: Breast Cancer Brain Metastases
Sites: Hefei, China; Guangzhou, China; Liuzhou, China · 25 sites in all
Shanghai Pharmaceuticals Holding Co., LtdIndustry
NCT05905614 · 29 participants · Start Nov 3, 2020 · Primary completion Oct 26, 2023
Drug: SPH4336 Tablets · For: Advanced Solid Tumors
Sites: Jinan, China; Chengdu, China; Beijing, China · 4 sites in all
Shanghai Pharma Biotherapeutics USA Inc.Industry
NCT05580588 · 14 participants · Start Aug 31, 2023 · Primary completion Oct 4, 2024
Drug: SPH4336 · For: Liposarcoma, Dedifferentiated
Sites: Phoenix, Arizona; Duarte, California; Jacksonville, Florida · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Correction to: Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.
· Oncologist 2026
- Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.
Jiang Y, Liang X, Sun ML, et al. · Oncologist 2025
Also in development for Locally Advanced or Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- LHRH AgonistPhase 36 trials
Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- SIM0270Phase 31 trial
Jiangsu Simcere Pharmaceutical Co., Ltd. · Locally Advanced or Metastatic Breast Cancer
- YL202 should be intravenously infusedPhase 22 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · NSCLC, Breast Cancer, HNSCC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.